Sipping On A Sam Adams Boston Lager In Front Of My Beautiful Computer Desk On My Desktop PC Making Money On The OTC!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RXPC ~ I wonder what all the HUGE loading that took place awhile back was about?
IMO
RXPC ~ Should there be news of a deal. Kaboom!
IMO
RXPC ~ Lenders could force them into a corner, haven't yet. See what happens when they are unable to sell anymore shares. That alone will cause this to run imo. Facts are enticing and hold promise of interest by others...
Why Onko-Sure a good test
~ It has an FDA clearance for colorectal cancer monitoring.
~ It has an Health Canada approval for the detection and
monitoring of lung cancer.
~ It has an indication for detecting all the solid tumors (19
cancer types)
~ There are many publications about this test in many
various cancer types.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
I admit there is much bad in the most recent Form 10-K. Financials completely and utterly horrible. Below are just some of the excerpts which I thought were positive. I still hold my ground in that Onko-Sure holds significant value. I think it's fair to say the chances of someone being interested in Radient are better than average. This was hinted towards in the most recent 8-K. If Onko-Sure were further developed it would hold even more promise. Though sales have been weak, there were an increase in sales up 35% from 2010-2011. If Onko-Sure were complete garbage increased sales of any sort wouldn't make sense. Sales increased during RXPC's horrible financial state which in my opinion speaks volumes. The approval by the FDA occurred in 2008. This announcement marks the first clearance to market a colorectal monitoring product that the USFDA has granted since January 14, 1982 when Carcinoembryonic Antigen (CEA) was approved. All things considered 2008 is fairly recent, in my opinion much to recent to write Onko-Sure off completely. I agree with the statement...The receipt of United States Food and Drug Administration (“USFDA”) clearance for marketing our proprietary Onko-Sure® cancer test kit in July 2008 has given us significant visibility in the in-vitroostics (“IVD”) industry.Would be very exciting and profitable for shareholders should anyone take over in further developing, marketing and increasing sales of Onko-Sure.
Anyway, no expert but I thought of all the bad noted in the most recent 10-K, the following excerpts inspire hope. I strongly believe there will be interest in Radient by someone, merger. Onko-Sure in my opinion holds promise, especially if further developed.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Excerpts from most recent 10-K
Filed 06/29/12 for the Period Ending 12/31/11
~ eventually create a “rapid test” format of Onko-Sure® test kit to extend sales into rural areas and Physician Owned Labs (“POL”)
~ USFDA clearance to market was based upon data showing that the Onko-Sure® test kit has the ability to monitor the progression of colorectal cancer post-surgery in patients who are biopsy confirmed with this disease. This announcement marks the first clearance to market a colorectal monitoring product that the USFDA has granted since January 14, 1982 when Carcinoembryonic Antigen (CEA) was approved. Until now, the CEA test has been the only accepted method cleared in the U.S. Thus, OnkoSure® test kit offers a new test that can monitor colorectal tumors post-surgery.
~ The Onko-Sure® test kit can be added easily and inexpensively to the pre-existing line of ELISA-based diagnostics performed routinely by clinical laboratories throughout the world. Furthermore, the Onko-Sure® test kit can be used in place of more costly and time consuming diagnostic tests. In clinical trials in U.S., China, Germany, Taiwan and Turkey, Onko-Sure® has been used as a screen for multiple cancers while only needing a single blood sample.
~ On July 3, 2008 we received a determination letter from the USFDA approving our application to market Onko-Sure® test kit as an immunology and microbiology device to monitor colorectal cancer under the category “Tumor Associated Antigens Immunological Test System” as a Class II IVD device. The receipt of United States Food and Drug Administration (“USFDA”) clearance for marketing our proprietary Onko-Sure® cancer test kit in July 2008 has given us significant visibility in the in-vitroostics (“IVD”) industry. The growth of the IVD marketplace has been driven by an increase in the incidence of cancer, other chronic and infectious diseases, emerging technologies and increasing patient awareness. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. (Cancer Diagnostic Testing World Markets, July 2011, www.reportlinker.com/p089470-summary/Cancer-Diagnostic-TestingWorld-Markets.html).
~ Many major medical device manufacturers, including Abbott Diagnostics, Baxter Healthcare Corp., Beckman Diagnostics, Boehringer Mannheim, Centocor, Diagnostic Products Corporation, Bio-Rad Laboratories, Roche Diagnostic Systems, Sigma Diagnostics and others, are manufacturers or marketers of other diagnostic products. We are not aware of any efforts currently being devoted to development of products such as our Onko-Sure® test kit; however, there can be no assurance that such efforts are not being undertaken without our knowledge. We believe that most of the diagnostic products currently manufactured by other companies are complementary to our Onko-Sure® test kit. Moreover, such companies could develop products similar to our products and they may be more successful in marketing and manufacturing their products. In addition, there are a number of new technologies in various stages of development at the National Institute of Health, university research centers and at other companies for the detection of various types of cancers, e.g., identification of proteomic patterns in blood
serum that distinguishes benign from cancerous conditions, which may compete with our product.
~ Virtually all of our operating revenues come from the sale of Onko-Sure® to distributors and research users. Historically, we have not received any substantial orders from any of our customers or distributors of Onko-Sure® test kits. Through December 31, 2011, total sales of OnkoSure® test kits were $313,559 as compared to $231,662 in total sales of such product in fiscal 2010. Due to the lack of funds, we are unable to continue the sales and marketing of our kits which impacts our efforts to increase or maintain our distribution network. In addition, the amount of Onko-Sure® test kits purchased by our distributors can be adversely affected by a number of factors, including market challenges of commercializing a recently approved biotech product, budget cycles and the amount of resources available for marketing programs, demand creation activities, and outreach to appropriate healthcare professionals and targeted markets. At this time, until we receive additional financing, it is likely that our sales efforts will cease.
Year Ended December 31, 2011 Compared to Year Ended December 31, 2010
2011 / 2010 / Difference %
Net revenues $ 313,559 / $ 231,662 / $ 81,897 / 35 %
**This increase of 35% is due to increased orders for the Onko-Sure® test kits.
Gross Profit
**Gross profit increased approximately 41% to $261,783 for the year ended December 31, 2011 from $185,337 for the year ended December 31, 2010 due to increased sales volume of the Onko-Sure® test kit.
~ Additional costs involved with consultants and the research conducted with CLIA Laboratories to expand on the clinical utility of Onko-Sure®;
~ Future Capital Needs
If funding is obtained, we expect to incur additional capital expenditures in 2012 in the form of re-starting operations by retaining qualified individuals for manufacturing, accounting and support staff. Depending on the extent of funding, we intend to re-start the project to further develop the Onko-Sure® test kit and upgrading manufacturing lines in Tustin.
Link: http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8697129
End Excerpts from most recent 8-K
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
** Just some random facts, might seem very random lol.
Nevertheless it's factual.
Comparison of Sensitivity
• The sensitivity of the combined test is 75%, which is 35% better
than the sensitivity of CEA alone. This is considered clinically
important in the management of colorectal cancer.
• Considering that there are not many FDA-cleared blood biomarkers
in the market for colorectal cancer recurrence monitoring, it is
advised to combine CEA, the routine colorectal cancer marker, with
DR-70 to increase the sensitivity of the test.
• Improvement in detection of recurrence has important implications to patient treatment options, prognosis and survival rate.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
• CEA is an adhesion molecule that is firmly attached to cancer
cells. Therefore, it is Less abundant in blood and more difficult to be measured. This is the case, especially in early stages because proteases stimulated during oncogenesis are required to release the membrane-bound antigen from the cancer cells.
• For many years (until 2008), CEA has been the only blood
biomarker cleared for the monitoring of the colorectal cancer.
• More than 35% of the CRC patients will experience recurrence at
some point. However, approximately half of these patients have
low CEA values not detectable by CEA test.
•For this very reason, Onko-Sure can be advantageous over CEA
in detecting lower levels of the blood biomarker leading to an early diagnosis of recurrence.
•Onko-Sure is a simple, non-invasive, ELISA-based assay in vitro
diagnostic (IVD) blood biomarker test for monitoring of colorectal cancer treatment and recurrence.
•There are 76 refereed publications from all over the world
supporting this blood biomarker alone and in combination with
other blood biomarkers for 19 different cancers.
•It was cleared by US FDA in 2008 for monitoring of colorectal
cancer treatment and recurrence.
• Onko-Sure measures the accumulation of the breakdown products
of Fibrin/Fibrinogen Degradation Products (FDP), including a
unique cancer-related breakdown product called “Initial Plasmin
Degradation Product” (IPDP) in the serum using an antibody
against DR-70 tumor marker.
• DR-70 is Freely diffusible in blood and therefore easy to measure even in low concentrations.
• Furthermore, CEA has approximately a 20% chance of false
positive in smokers while, Onko-Sure measurements are not
affected by smoking.
• A combination of several tumor markers is well known to provide
more accurate information about detection and monitoring of
many different types of diseases including cancers.
• This was the case reported by many independent scientists for
combined CEA and DR-70 blood biomarkers as well.
• Our results were also in line with the previously published
manuscripts in the peer-reviewed journals showing an improved
sensitivity of the combined test compared to either of them.
• Early diagnosis of relapsing malignancies is important for
planning future therapeutic strategies which, if initiated without
delay, aim either to cure or to prolong disease-free survival and to improve the quality of life of patients with cancer.
• If a new diagnostic test increases early detection of CRC
recurrence when used adjunctively with other available diagnostic
markers, the annual deaths due to CRC recurrence could be
reduced due to early detection and increased survival rates.
• Therefore, it is recommended that both CEA and Onko-Sure be
used in combination for the monitoring of CRC treatment as well
Horrible Financial State...
2011 Total assets/ 2011 Total liabilities
$1,176,140 / $50,865,998
Despite the horrible state of affairs, I still think there is a very strong possibility of a Merger.
Expecting much, RXPC will rock in 2013!
IMO
RXPC ~ It's not uncommon for opinions to change in anything Cancer related. After Steve Jobs passed (Greatest Marketer Of All Time!)
there were serious doubts/questions raised towards pancreatic cancer testing. I know Onko-Sure is non-evasive, but do feel should someone come along and further market, develop and increase sales, could really take off. If there is a deal worked out it's always hard to gauge where current stakeholder's will stand. I'm sure there would be significant changes to the current share structure, although depending how the chips fall it could still be a pretty penny. Should news of that sort come about, I imagine there would be a healthy run prior to any change in the share structure. Again, I am speculating on all of this and don't claim to be an expert... could easily be wrong. I obviously don't think I am but I've been wrong in the past. Everyone should do their own DD and obviously there are TONS of people out there who know much more than I do lol. Just holding my stance with my thought process being Onko-Sure is anything but garbage and does have value. In the end this will do what is does. Interesting to see what takes place. Always fun conversing back and forth with differing stock opinions. Always good to keep at it and try to learn all you can. Without both sides there wouldn't even be a market. So game on lol!
IMO
RXPC ~ All in fun, that picture is pretty funny. Should anyone come along and further market, develop and increase sales of Onko-Sure could get exciting quick. Even with the current debt I imagine there will be interest. Look at how sales increased with practically no marketing while in a horrible financial state. Sales were not great, but I think they could be. Onko-Sure has many strengths imo.
RXPC ~ Very likely and reasonable to think RXPC will have significant interest. Looking for and expecting something to transpire. Only makes sense, Onko-Sure has value and to much potential for this to be dead imo. RXPC will explode in 2013! RXPC will bring an early Christmas. Huge Value from down here. With all do respect I also believe you are dead wrong.
RXPC ~ I agree upon all the bad that you listed from the most recent 10-K, it's there in black and white. I just pointed out what I took to be positive. Onko-Sure holds definitive value, fact. In my opinion there will be interest. Makes perfect sense, definitely a reasonable speculation. IMO.
~ GO RXPC!
RXPC ~ 2013 Year of RXPC. Going to explode should anything transpire as hinted in last 8-K.
- Go RXPC!
RXPC ~ I was wrong about the patents in post #12414, so I asked it be removed. There are two pending patent applications initially filed in 2009 that are still in the approval process. The trademarks for DR-70 and Onko-sure renew in 2019.
Why Onko-Sure a good test
~ It has an FDA clearance for colorectal cancer monitoring.
~ It has an Health Canada approval for the detection and
monitoring of lung cancer.
~ It has an indication for detecting all the solid tumors (19
cancer types)
~ There are many publications about this test in many
various cancer types.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
I admit there is much bad in the most recent Form 10-K. Financials completely and utterly horrible. Below are just some of the excerpts which I thought were positive. I still hold my ground in that Onko-Sure holds significant value. I think it's fair to say the chances of someone being interested in Radient are better than average. This was hinted towards in the most recent 8-K. If Onko-Sure were further developed it would hold even more promise. Though sales have been weak, there were an increase in sales up 35% from 2010-2011. If Onko-Sure were complete garbage increased sales of any sort wouldn't make sense. Sales increased during RXPC's horrible financial state which in my opinion speaks volumes. The approval by the FDA occurred in 2008. This announcement marks the first clearance to market a colorectal monitoring product that the USFDA has granted since January 14, 1982 when Carcinoembryonic Antigen (CEA) was approved. All things considered 2008 is fairly recent, in my opinion much to recent to write Onko-Sure off completely. I agree with the statement...The receipt of United States Food and Drug Administration (“USFDA”) clearance for marketing our proprietary Onko-Sure® cancer test kit in July 2008 has given us significant visibility in the in-vitroostics (“IVD”) industry.Would be very exciting and profitable for shareholders should anyone take over in further developing, marketing and increasing sales of Onko-Sure.
Anyway, no expert but I thought of all the bad noted in the most recent 10-K, the following excerpts inspire hope. I strongly believe there will be interest in Radient by someone, merger. Onko-Sure in my opinion holds promise, especially if further developed.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Excerpts from most recent 10-K
Filed 06/29/12 for the Period Ending 12/31/11
~ eventually create a “rapid test” format of Onko-Sure® test kit to extend sales into rural areas and Physician Owned Labs (“POL”)
~ USFDA clearance to market was based upon data showing that the Onko-Sure® test kit has the ability to monitor the progression of colorectal cancer post-surgery in patients who are biopsy confirmed with this disease. This announcement marks the first clearance to market a colorectal monitoring product that the USFDA has granted since January 14, 1982 when Carcinoembryonic Antigen (CEA) was approved. Until now, the CEA test has been the only accepted method cleared in the U.S. Thus, OnkoSure® test kit offers a new test that can monitor colorectal tumors post-surgery.
~ The Onko-Sure® test kit can be added easily and inexpensively to the pre-existing line of ELISA-based diagnostics performed routinely by clinical laboratories throughout the world. Furthermore, the Onko-Sure® test kit can be used in place of more costly and time consuming diagnostic tests. In clinical trials in U.S., China, Germany, Taiwan and Turkey, Onko-Sure® has been used as a screen for multiple cancers while only needing a single blood sample.
~ On July 3, 2008 we received a determination letter from the USFDA approving our application to market Onko-Sure® test kit as an immunology and microbiology device to monitor colorectal cancer under the category “Tumor Associated Antigens Immunological Test System” as a Class II IVD device. The receipt of United States Food and Drug Administration (“USFDA”) clearance for marketing our proprietary Onko-Sure® cancer test kit in July 2008 has given us significant visibility in the in-vitroostics (“IVD”) industry. The growth of the IVD marketplace has been driven by an increase in the incidence of cancer, other chronic and infectious diseases, emerging technologies and increasing patient awareness. Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. (Cancer Diagnostic Testing World Markets, July 2011, www.reportlinker.com/p089470-summary/Cancer-Diagnostic-TestingWorld-Markets.html).
~ Many major medical device manufacturers, including Abbott Diagnostics, Baxter Healthcare Corp., Beckman Diagnostics, Boehringer Mannheim, Centocor, Diagnostic Products Corporation, Bio-Rad Laboratories, Roche Diagnostic Systems, Sigma Diagnostics and others, are manufacturers or marketers of other diagnostic products. We are not aware of any efforts currently being devoted to development of products such as our Onko-Sure® test kit; however, there can be no assurance that such efforts are not being undertaken without our knowledge. We believe that most of the diagnostic products currently manufactured by other companies are complementary to our Onko-Sure® test kit. Moreover, such companies could develop products similar to our products and they may be more successful in marketing and manufacturing their products. In addition, there are a number of new technologies in various stages of development at the National Institute of Health, university research centers and at other companies for the detection of various types of cancers, e.g., identification of proteomic patterns in blood
serum that distinguishes benign from cancerous conditions, which may compete with our product.
~ Virtually all of our operating revenues come from the sale of Onko-Sure® to distributors and research users. Historically, we have not received any substantial orders from any of our customers or distributors of Onko-Sure® test kits. Through December 31, 2011, total sales of OnkoSure® test kits were $313,559 as compared to $231,662 in total sales of such product in fiscal 2010. Due to the lack of funds, we are unable to continue the sales and marketing of our kits which impacts our efforts to increase or maintain our distribution network. In addition, the amount of Onko-Sure® test kits purchased by our distributors can be adversely affected by a number of factors, including market challenges of commercializing a recently approved biotech product, budget cycles and the amount of resources available for marketing programs, demand creation activities, and outreach to appropriate healthcare professionals and targeted markets. At this time, until we receive additional financing, it is likely that our sales efforts will cease.
Year Ended December 31, 2011 Compared to Year Ended December 31, 2010
2011 / 2010 / Difference %
Net revenues $ 313,559 / $ 231,662 / $ 81,897 / 35 %
**This increase of 35% is due to increased orders for the Onko-Sure® test kits.
Gross Profit
**Gross profit increased approximately 41% to $261,783 for the year ended December 31, 2011 from $185,337 for the year ended December 31, 2010 due to increased sales volume of the Onko-Sure® test kit.
~ Additional costs involved with consultants and the research conducted with CLIA Laboratories to expand on the clinical utility of Onko-Sure®;
~ Future Capital Needs
If funding is obtained, we expect to incur additional capital expenditures in 2012 in the form of re-starting operations by retaining qualified individuals for manufacturing, accounting and support staff. Depending on the extent of funding, we intend to re-start the project to further develop the Onko-Sure® test kit and upgrading manufacturing lines in Tustin.
Link: http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=8697129
End Excerpts from most recent 8-K
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
** Just some random facts, might seem very random lol.
Nevertheless it's factual.
Comparison of Sensitivity
• The sensitivity of the combined test is 75%, which is 35% better
than the sensitivity of CEA alone. This is considered clinically
important in the management of colorectal cancer.
• Considering that there are not many FDA-cleared blood biomarkers
in the market for colorectal cancer recurrence monitoring, it is
advised to combine CEA, the routine colorectal cancer marker, with
DR-70 to increase the sensitivity of the test.
• Improvement in detection of recurrence has important implications to patient treatment options, prognosis and survival rate.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
• CEA is an adhesion molecule that is firmly attached to cancer
cells. Therefore, it is Less abundant in blood and more difficult to be measured. This is the case, especially in early stages because proteases stimulated during oncogenesis are required to release the membrane-bound antigen from the cancer cells.
• For many years (until 2008), CEA has been the only blood
biomarker cleared for the monitoring of the colorectal cancer.
• More than 35% of the CRC patients will experience recurrence at
some point. However, approximately half of these patients have
low CEA values not detectable by CEA test.
•For this very reason, Onko-Sure can be advantageous over CEA
in detecting lower levels of the blood biomarker leading to an early diagnosis of recurrence.
•Onko-Sure is a simple, non-invasive, ELISA-based assay in vitro
diagnostic (IVD) blood biomarker test for monitoring of colorectal cancer treatment and recurrence.
•There are 76 refereed publications from all over the world
supporting this blood biomarker alone and in combination with
other blood biomarkers for 19 different cancers.
•It was cleared by US FDA in 2008 for monitoring of colorectal
cancer treatment and recurrence.
• Onko-Sure measures the accumulation of the breakdown products
of Fibrin/Fibrinogen Degradation Products (FDP), including a
unique cancer-related breakdown product called “Initial Plasmin
Degradation Product” (IPDP) in the serum using an antibody
against DR-70 tumor marker.
• DR-70 is Freely diffusible in blood and therefore easy to measure even in low concentrations.
• Furthermore, CEA has approximately a 20% chance of false
positive in smokers while, Onko-Sure measurements are not
affected by smoking.
• A combination of several tumor markers is well known to provide
more accurate information about detection and monitoring of
many different types of diseases including cancers.
• This was the case reported by many independent scientists for
combined CEA and DR-70 blood biomarkers as well.
• Our results were also in line with the previously published
manuscripts in the peer-reviewed journals showing an improved
sensitivity of the combined test compared to either of them.
• Early diagnosis of relapsing malignancies is important for
planning future therapeutic strategies which, if initiated without
delay, aim either to cure or to prolong disease-free survival and to improve the quality of life of patients with cancer.
• If a new diagnostic test increases early detection of CRC
recurrence when used adjunctively with other available diagnostic
markers, the annual deaths due to CRC recurrence could be
reduced due to early detection and increased survival rates.
• Therefore, it is recommended that both CEA and Onko-Sure be
used in combination for the monitoring of CRC treatment as well
Horrible Financial State...
2011 Total assets/ 2011 Total liabilities
$1,176,140 / $50,865,998
Despite the horrible state of affairs, I still think there is a very strong possibility of a Merger.
Expecting much, RXPC will rock in 2013!
IMO
RXPC ~ If I'm incorrect about the patent just let me know and I'll ask to have the post removed or admit I was wrong. I have no idea as to what could be taking place if anything at all. Just speculating on what was hinted towards in the last 8-K/A. Like I say, I think there is value here much more than triple zero one. Just my take.
IMO
RXPC ~ 2013 will be a GREAT year for RXPC! Looking forward to the possibility of good things to come.
- Go RXPC!
IMO
RXPC~
Colorectal cancer screening tests
Flexible sigmoidoscopy
Pros
~Fairly quick and safe
~Usually doesn't require full bowel preparation
~Sedation usually not used
~Does not require a specialist
~Done every 5 years
Cons
~Views only about a third of the colon
~Can miss small polyps
~Can't remove all polyps
~May be some discomfort
~Very small risk of bleeding, infection, or bowel tear
~Colonoscopy will be needed if abnormal
Colonoscopy
Pros
~Can usually view entire colon
~Can biopsy and remove polyps
~Done every 10 years
~Can diagnose other diseases
Cons
~Can miss small polyps
~Full bowel preparation needed
~More expensive on a one-time basis than other forms of testing
~Sedation of some kind is usually needed
~Will need someone to drive you home
~You may miss a day of work
~Small risk of bleeding, bowel tears, or infection
Double-contrast barium enema (DCBE)
Pros
~Can usually view entire colon
~Relatively safe
~Done every 5 years
~No sedation needed
Cons
~Can miss small polyps
~Full bowel preparation needed
~Some false positive test results
~Cannot remove polyps during testing
~Colonoscopy will be needed if abnormal
CT colonography (virtual colonoscopy)
Pros
~Fairly quick and safe
~Can usually view entire colon
~Done every 5 years
~No sedation needed
Cons
~Can miss small polyps
~Full bowel preparation needed
~Some false positive test results
~Cannot remove polyps during testing
~Colonoscopy will be needed if abnormal
~Still fairly new - may be insurance issues
Fecal occult blood test (FOBT)
Pros
~No direct risk to the colon
~No bowel preparation
~Sampling done at home
~Inexpensive
Cons
~May miss many polyps and some cancers
~May produce false-positive test results
~May have pre-test dietary limitations
~Should be done every year
~Colonoscopy will be needed if abnormal
Fecal immunochemical test (FIT)
Pros
~No direct risk to the colon
~No bowel preparation
~No pre-test dietary restrictions
~Sampling done at home
~Fairly inexpensive
Cons
~May miss many polyps and some cancers
~May produce false-positive test results
~Should be done every year
~Colonoscopy will be needed if abnormal
Last Medical Review: 06/05/2012
Last Revised: 01/24/2013
Link:http://www.cancer.org/cancer/colonandrectumcancer/moreinformation/colonandrectumcancerearlydetection/colorectal-cancer-early-detection-screening-tests-used
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
BLOOD TESTS THAT SHOW CANCER
CEA TESTING
One blood test that can be used as a diagnostic tool for cancer is CEA testing. CEA stands for carcinogenic embryonic antigen, an antigen found in cancer cells. During cancer development, growth of some types of cancer cells leads to the increased secretion of CEA into the blood. A CEA test assesses the levels of CEA in the blood, with high levels of CEA indicating the presence of cancer. According to the BC Cancer Agency, CEA testing is primarily used to help test for and monitor colorectal cancer. Patients may receive regular CEA testing throughout cancer therapy, since a decrease in CEA levels can indicate successful cancer treatment, and sustained low levels after treatment can indicate a lack of cancer recurrence.
ONKO-SURE
Another type of cancer blood test is Onko-Sure, which can detect a number of different cancers. According to Radient Pharmaceuticals, the test's developer, the Onko-Sure blood test can detect the presence of 14 types of cancer. This test is especially useful in testing for cancers that do not secrete other cancer markers, such as CEA. As a result, an Onko-Sure test can help identify cancers that other blood tests may miss. The test indicates the presence of protein fragments called FDPs, which occur when cancer cells break down their surroundings to facilitate more cancer growth. The Onko-Sure test checks for the presence of several FDPs and, therefore, acts as a sensitive test for several forms of cancer, reports Radient Pharmaceuticals.
CBC TEST
A complete blood count test, or CBC test, can also aid in cancer diagnosis, according to MayoClinic.com. During a CBC test, the doctor collects a sample of blood, and tests for the cell composition for the blood sample. A CDC test can indicate the presence of abnormal cells that might occur in a blood related cancer. The test may also help diagnose metastatic cancers, since cancer cells often travel throughout the body in the bloodstream and may be detected in a blood sample. Although a CDC test can indicate the presence of cancer, doctors must perform additional testing to learn the origin and characteristics of the cancer.
Date: Last updated on: May 3, 2011
Link: http://www.livestrong.com/article/196618-blood-tests-that-show-cancer/
RXPC ~ Per most recent 8-K/A...
From an operational perspective, we continue to sell and ship Onko-Sure test kits to the following territories: Korea, Turkey, Taiwan, India,
Vietnam, and the U.S. Despite significant financial hardship, the Company continues to maintain its operations in Tustin, relying on selective
former employees that continue to work as consultants to the Company. We are also engaged in business discussions with other companies
seeking to license Onko-Sure for various international territories. These licensing agreements, if completed, are anticipated to provide the
Company with the funds necessary to regain compliance with our public filing requirements and to begin to pay down various overdue
accounts payable. There can be no guarantee that any new licensing transactions will be completed.
IMO
RXPC ~ Speculating towards merger, don't know for sure obviously. Hinted towards in the last 8-K. RXPC still kicking, Onko-Sure holds value and I would speculate others agree. Speculating on and hoping for a deal. Makes the most sense to me.
IMO
RXPC ~ How could it be a scam when it once traded on the AMEX and was highly transparent, but it's yet to be halted/shutdown? RXPC has been around now for a looong time, no halt. Say what you want about Onko-Sure but the FDA doesn't approve scams. Financially horrible I agree. Speculating on a merger. Makes perfect sense to me, could be wrong.
IMO
RXPC ~ Can't wait to hear what could or is taking place behind the scenes! Last 8-K suggested something is in the works. Confident there is interest in Onko-Sure (DR-70).
IMO
RXPC ~ Colorectal cancer is being diagnosed at in increasing rate, awareness has increased tremendously in recent time. If there is one sector that is forever changing it is the medical community. What has kept Onko-Sure afloat for so long, it obviously has some worth. There are patients currently being tested using Onko-Sure?? Onko-Sure has definitive worth in my opinion without question. There have been articles stating Onko-Sure when used in conjunction with CEA showing increased accuracy in testing. I'm speculating on some sort of deal/acquisition, which I feel is not out of the realm of reality by any means. I disagree that Onko-Sure has no value in screening for Colon cancer. The fact that 40% of people needing screened are not being screened is a tell tale sign that colon cancer is a much bigger problem than it used to be and anything to improve testing methods so those suffering are properly diagnosed is monumental. Should any deal/acquisition take place, depending on the workings of the deal...could be huge from all the way down here. Just my take, I remain optimistic towards Radient. RXPC will get it's rear in gear!
IMO
RXPC ~ 40% of people who should be tested aren't getting tested for colorectal cancer. In my opinion Onko-Sure (DR-70) has definable strengths lacking with CEA. CEA has definable strengths lacking with Onko-Sure, both have their pros and cons. With caner awareness and concern on the rise especially colorectal cancer, efficient testing methods are dire. Cancer is big business. Speculating on some sort of deal is not a pipe dream imo.
LOL, no kidding and who has made money 100% of the time. Go RXPC!
RXPC ~ I'm in your camp, definite value in Onko-Sure and confident some other entity will agree. Speculating on some sort of deal. Only makes sense to me. Don't agree at all the product is garbage. Agree on the horrible state of the company, but don't agree it's over by any means. Like it from down here. Should anything transpire from here, could be very nice.
IMO
RXPC ~ Lots of no bid stocks have had serious runs. Like I say, not saying this will. I am speculating and like this one. Not saying I'm some sort of expert. Nothing more nothing less. Go RXPC!
IMO
Not expecting any news soon based on the low low volume. I don't know that there will be any news at all. I just think that there is value in Onko-Sure and speculate someone will feel the same. Could be wrong. Not like it's uncommon for any penny stock to go from low to high volume practically over night. Seems like the people who really know this game like to hop on something hot in the moment that will yield gains quickly. IDK, my opinion anyway. If you are that good why put your money to sleep while waiting on something you feel might go up when you can make today money, short term gains. Penny stocks are so volatile not uncommon to see 20 - 30% swings in a day, higher than that even. Not like I'm saying anything that nobody else knows. I'm being Mr. obvious here. I mean volume right now suggest this is dead, zero interest right now I agree. I just don't feel that 100% suggest this is dead for good. Can change on a dime, just my opinion. Once again could be wrong.
IMO
RXPC ~ I beg to differ, regardless of popular opinion I don't feel RXPC is dead and gone. Onko-Sure sales in the past have been lack luster without question. Financial state is horrible. I still think that Onko-Sure holds value and am confident someone will feel the same. Hoping for announcements of some sort, when and if is anyone's guess. I thought the last 8-K hinted towards the possibility of a deal. If anything time is on RXPC's side going forward. If this were over wouldn't it have been over by now? IDK, that's just my two cents. Not that anyone cares nor should they. Thought I'd just throw it out there on the sounding board. Obviously I could be wrong. Regardless, hope this goes up. Go RXPC!
IMO
RXPC ~ Despite the horrible financial state and implausible hurdles going forward. I remain optimistic towards RXPC and still think Onko-Sure holds value. Complete Risk but like the odds, hoping for something to transpire.
IMO
OK , now three bucks a share is pumping lol. What would the market capitalization be at three bucks with this share structure. Don't worry though .003 + is very real. You have no worries though right, you know for sure it's junk with no hope going forward. I at least admit to the possibility of both good and bad. Like I say though, I feel good about this.
IMHO
RXPC ~ How would I know. It's pretty easy in my opinion to rank on a no bid (.0001) stock with zero volume. Obviously RXPC has major hurdles to overcome and a lackluster past. I thought any stock at .0001 was known to have major problems, thought that was a gimme. If I was right about every stock I would be a millionaire umpteen times over investing money in a much different asset class. Different risk factors for different objectives. I know RXPC is high high risk with a good possibility of losing 100% of my investment. I think there is value in RXPC and excited about the possibility of things to come when buying in @ .0001. I've been wrong before and I'm sure I'll be wrong again at some point going forward. I like how when you like a stock your called a pumper. To me a pumper is someone touting completely unrealistic gains and falsities about the company. What is the name given to someone who just likes a stock lol, unreal. Once again I think there is value here and expecting much going forward, just my opinion. Not pumping or hyping. I do think .002 + is completely realistic should anything transpire. I could envision much higher actually. See what happens.
RXPC ~ Wait till this is at .002+, which will look cheap when and if it happens. Waaaay undervalued IMHO.
40% of people who should be getting screened for colon cancer are not. Thousands of patients are currently tested using Onko-Sure. Colon cancer awareness is on the rise as it should be. Onko-Sure has definable strengths that are lacking with CEA. Both test have their strengths and weaknesses in my opinion. Both test hold value.
Onko-Sure in no way should be trash canned. This would have been over by now if it were going to happen imo. The possibility of something substantial taking place is exciting from waaaaaaay down here at .0001 See what happens. I'm speculating and of course could be wrong.
RXPC is going to get it's rear in gear in 2013!
IMO
RXPC ~ I would agree that most triple zero stocks are anything but desirable and would go as far as to call some POS. However, I really don't consider RXPC to be a POS. I could be wrong obviously but I think there is value in Onko-Sure.
IMHO
RXPC ~ Not hyping anything. Obviously a dead stock as of now. PLENTY of stocks that were once DEAD have come out of the gutter yielding nice gains. I just feel this is not over yet. Of course I could be wrong, total speculation on my part. To each his own, time will tell the tale. Interesting to see what comes about if anything at all. I remain positive from down here.
IMO
RXPC ~ I feel RXPC is anything but dead and gone. Speculating on good things to come.
IMO
No Worries mate. RXPC grand slam Baby Ruth Style.
2013, WOW! Period! No hope anymore. FACT! In my opinion. Hope is gone, fact is here.
You know, I think you are 2000% correct!
IMO
I'm calling this one, Babe Ruth style. Over the fences outfielders, put your gloves down. Not much Point.
WOW! RXPC is going to rock this year. Mark it down. Save this post please.
IMO
I know, no volume days. Crazy though how things can change over night in OTC land. So many No Bid stocks with an ask of .0001 wake up over night run up to .0007 +. Not just triple zero though, can happen with any OTC. Things can go cold to hot overnight and vice versa.
IMO
MMTC working with a lot of high profile agencies to be a scam. Buy on fear sell on cheer. OMG .0001 makes my mouth water lol. It will never come, fact.
I have high hopes for Radient in 2013. Go RXPC!